Discontinuation of Follow-up Care Among Women With Early-Stage Breast Cancer


Key Points

  • In total, 21% of women discontinued follow-up care over 5 years from diagnosis.
  • Factors in discontinuation included older age, hormone receptor–negative disease, low tumor grade, single vs married status, less recent year of diagnosis, and lower disease stage.

In a study using linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data reported in the Journal of Oncology Practice, Quyyumi et al found that 21% of women with early-stage breast cancer discontinued follow-up care within 5 years after diagnosis.

Study Details

The study involved data on 30,053 women aged ≥ 65 years diagnosed with stage I or II breast cancer who underwent breast-conserving surgery within 6 months of diagnosis between January 2002 and December 2007. Follow-up was through December 2012. Discontinuation of follow-up was defined as a period > 12 months from the previous physician visit without a visit claim from a surgeon, medical oncologist, or radiation oncologist.

Discontinuation and Associated Factors

Of the 30,053 patients, 25,781 (85.8%) saw a medical oncologist and 21,612 (71.9%) a radiation oncologist in the first year in addition to their surgeon; 66% saw all 3 providers during the first year. By 5 years, 6,302 patients (21.0%) discontinued follow-up visits with any oncology provider. On multivariate analysis, factors significantly associated with discontinuation (all P < .05) were increasing age (hazard ratios of 1.11, 1.21, and 1.68 for 70–74, 75–79, and ≥ 80-year age groups vs age 65–69 years), presence of hormone receptor–negative disease (HR = 1.14), low vs high tumor grade (HR = 1.07), and single vs married status (HR = 1.09). Factors significantly associated (P < .05) with reduced likelihood of discontinuation were stage II vs stage I disease (HR = 0.83) and more recent year of diagnosis (HR = 0.96).

Overall, the number of patients seeing only a medical oncologist increased each year, with visits to only a radiation oncologist or surgeon decreasing in years 2 to 5; by year 5, the majority of patients had fewer than two visits with an oncology provider.

The investigators concluded, “Twenty-one percent of patients with early-stage breast cancer discontinued seeing any oncology provider over the 5 years after diagnosis. Coordination of follow-up care between oncology specialists may reduce discontinuation rates and increase clinical efficiency.”

The study was supported by grants from the ASCO/Breast Cancer Research Foundation and National Cancer Institute.

Dawn L. Hershman, MD, of Columbia University Medical Center, is the corresponding author for the Journal of Oncology Practice article.

Disclosure: See study authors’ full disclosures at

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.